Affiliation:
1. From the Department of Clinical Sciences (Valerius, Ogilvie) and the Diagnostic Laboratory (Getzy), College of Veterinary Medicine and Biomedical Sciences, and the Department of Statistics (Mallinckrodt), College of Natural Sciences, Colorado State University, Fort Collins, CO 80523. Dr. Getzy's present address is Veterinary Services, 2150 W 6th Ave, Unit F, Broomfield, CO 80020.
Abstract
Objective
To determine response rate and remission as well as survival times for dogs with multicentric lymphoma treated first with doxorubicin alone or in combination with asparaginase and then with cyclophosphamide, vincristine sulfate, and prednisone (CVP) and to identify prevalence of toxicoses associated with this protocol and factors associated with prognosis.
Design
Retrospective case series.
Animals
121 dogs.
Procedure
Variables evaluated for prognostic value were initial response rate to chemotherapy, age, breed, sex, body weight, histologic grade, clinical stage and substage, previous corticosteroid treatment, and serum calcium concentration.
Results
Median overall remission and survival times for all 121 dogs were 205 and 237 days, respectively. Response rate (complete or partial response) was 88%. Ten dogs were hospitalized because of toxicoses associated with doxorubicin, and 19 dogs were hospitalized because of toxicoses associated with CVP. Asparaginase favorably influenced the initial response rate, but did not significantly influence overall remission or survival times. Initial response rate to chemotherapy, body weight. clinical substage, and serum calcium concentration was found to have prognostic value.
Clinical Implications
For dogs with multicentric lymphoma, treatment with doxorubicin alone or in combination with asparaginase and then with CVP resulted in an acceptable response rate and low prevalence of toxicoses. (J Am Vet Med Assoc 1997;210:512–516)
Publisher
American Veterinary Medical Association (AVMA)
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Novel Treatments for Lymphoma;Veterinary Clinics of North America: Small Animal Practice;2024-01